drugset / Trial / NCT02457819

Dasotraline Pediatric Extension Study

NCT02457819

Phase 3 Completed 237 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open label 26 week extension study for subjects who completed SEP360-202.

Timeline

Start
2015-06-30
Primary completion
2017-02-02
Completion
2017-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasotraline Small molecule 2 mg
Subject Dasotraline Small molecule 4 mg
Subject Dasotraline Small molecule 6 mg